Treeline Biosciences · Series A

Computational and experimental drug discovery for hard-to-drug cancer targets

Amount

$200M

Round

Series A

Valuation

—

Announced

Aug 2025

Investors

Participating investors

Google Ventures ARCH Venture Partners OrbiMed KKR Fidelity Investments Rock Springs Capital Access Industries Ajax Health Casdin Capital Aisling Capital Exor